Patent: 8,404,809
✉ Email this page to a colleague
Summary for Patent: 8,404,809
| Title: | Glycopegylated factor IX |
| Abstract: | Conjugates between Factor IX and PEG moieties are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. |
| Inventor(s): | DeFrees Shawn, Bayer Robert J., Bowe Caryn L., Panneerselvam Krishnasamy |
| Assignee: | Novo Nordisk A/S |
| Application Number: | US12605028 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,404,809
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | REBINYN | coagulation factor ix (recombinant), glycopegylated | For Injection | 125611 | May 31, 2017 | ⤷ Start Trial | 2029-10-23 |
| Novo Nordisk Inc. | REBINYN | coagulation factor ix (recombinant), glycopegylated | For Injection | 125611 | August 11, 2022 | ⤷ Start Trial | 2029-10-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,404,809
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200901943 | ⤷ Start Trial |
| South Africa | 200802543 | ⤷ Start Trial |
| South Africa | 200708564 | ⤷ Start Trial |
| South Africa | 200706242 | ⤷ Start Trial |
| South Africa | 200706130 | ⤷ Start Trial |
| South Africa | 200706129 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
